CN101704872B - 23-羟基白桦酸衍生物、其制备方法及应用 - Google Patents
23-羟基白桦酸衍生物、其制备方法及应用 Download PDFInfo
- Publication number
- CN101704872B CN101704872B CN2009101865366A CN200910186536A CN101704872B CN 101704872 B CN101704872 B CN 101704872B CN 2009101865366 A CN2009101865366 A CN 2009101865366A CN 200910186536 A CN200910186536 A CN 200910186536A CN 101704872 B CN101704872 B CN 101704872B
- Authority
- CN
- China
- Prior art keywords
- acid
- zhangnan
- hydroxyl radical
- compound
- white
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCCC(C)(C)C(CC1)C(C)(C)C(C)(CC2)C1C(C(CC1)*=C)C21C(O)=O Chemical compound CCCC(C)(C)C(CC1)C(C)(C)C(C)(CC2)C1C(C(CC1)*=C)C21C(O)=O 0.000 description 1
- SIIZJYDRBIOWMC-UHFFFAOYSA-N CCCC(C)(C)C(CC1)C(C)(C)C(C)(CC2)C1C(C(CC1)C(C)C)C21C(O)=O Chemical compound CCCC(C)(C)C(CC1)C(C)(C)C(C)(CC2)C1C(C(CC1)C(C)C)C21C(O)=O SIIZJYDRBIOWMC-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
人肿瘤细胞株 | 细胞类型 | zhangnan-5EC50(uM) | zhangnan-7EC50(uM) | zhangnan-8EC50(uM) |
LnCAP | 前列腺 | 0.69 | 15.6 | 7.8 |
D145 | 前列腺 | 0.85 | 14.8 | 8.4 |
PC3 | 前列腺 | 0.91 | 16.2 | 8.9 |
HCT-116 | 结肠 | 0.09 | 15.1 | 7.8 |
Widr | 结肠 | 0.28 | 14.8 | 8.1 |
HT29 | 结肠 | 0.47 | 13.9 | 8.9 |
LoVo | 结肠 | 0.15 | 15.2 | 9.6 |
CCL-225 | 结肠 | 0.23 | 16.1 | 8.6 |
CCL-247 | 结肠 | 0.52 | 15.6 | 8.2 |
NCI-H23 | 肺 | 0.32 | 12.8 | 6.7 |
A549 | 肺 | 0.54 | 13.1 | 6.9 |
MDA-MB-231 | 乳腺 | 0.47 | 17.5 | 7.2 |
MDA-MB-435 | 乳腺 | 0.55 | 19.3 | 7.9 |
AU-565 | 乳腺 | 0.59 | 18.2 | 6.8 |
BT-549 | 乳腺 | 0.67 | 17.4 | 7.4 |
MCF-7 | 乳腺 | 0.58 | 16.9 | 7.8 |
Caki-1 | 肾 | 0.98 | 20.1 | 9.2 |
ACHN | 肾 | 1.2 | 18.3 | 8.9 |
786-O | 肾 | 3.1 | 16.8 | 8.1 |
SN12C | 肾 | 1.3 | 17.5 | 7.6 |
SKOV3 | 卵巢 | 1.5 | 16.9 | 6.9 |
IGROV1 | 卵巢 | 2.1 | 17.4 | 7.2 |
Mid PaCa-2 | 胰腺 | 0.93 | 18.9 | 9.4 |
U-251 | 恶性胶质瘤 | 0.089 | 17.8 | 5.6 |
SK-MEL-5 | 皮肤(黑色 | 0.093 | 18.5 | 4.9 |
G-361 | 皮肤(黑色 | 0.087 | 19.3 | 5.3 |
MCF-10a | 正常乳腺上皮细胞 | >30 | >30 | >30 |
SGC-7901 | 胃 | 0.89 | 18.5 | 8.9 |
EC109 | 食管 | 0.78 | 17.9 | 9.5 |
CNE-2Z | 鼻咽 | 1.3 | 19.2 | 10.2 |
Raji | 淋巴瘤 | 0.098 | 20.5 | 6.9 |
Jurkat | 白血病T细 | 0.14 | 21.3 | 7.1 |
MEF | 正常小鼠成纤维细胞 | >30 | >30 | >30 |
药代动力学参数 | 均数+/-标准差 |
T1/2(hour) | 11.5+/-0.8 |
Tmax(min) | 85+/-7 |
Cmax(uM) | 65+/-9 |
Claims (7)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101865366A CN101704872B (zh) | 2009-11-23 | 2009-11-23 | 23-羟基白桦酸衍生物、其制备方法及应用 |
PCT/CN2010/072740 WO2011060634A1 (zh) | 2009-11-23 | 2010-05-13 | 23-羟基白桦酸衍生物、其制备方法及应用 |
US13/511,399 US20120302530A1 (en) | 2009-11-23 | 2010-05-13 | 23-hydroxy-betulinic acid derivatives, preparation methods and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101865366A CN101704872B (zh) | 2009-11-23 | 2009-11-23 | 23-羟基白桦酸衍生物、其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101704872A CN101704872A (zh) | 2010-05-12 |
CN101704872B true CN101704872B (zh) | 2012-06-27 |
Family
ID=42375131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101865366A Expired - Fee Related CN101704872B (zh) | 2009-11-23 | 2009-11-23 | 23-羟基白桦酸衍生物、其制备方法及应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20120302530A1 (zh) |
CN (1) | CN101704872B (zh) |
WO (1) | WO2011060634A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101704872B (zh) * | 2009-11-23 | 2012-06-27 | 张南 | 23-羟基白桦酸衍生物、其制备方法及应用 |
CN101961339B (zh) * | 2010-10-21 | 2012-01-04 | 中国药科大学 | 23-hba在制备降低阿霉素所致心脏毒性的药物中的应用 |
CN111417384A (zh) | 2017-09-14 | 2020-07-14 | 菲尼克斯生物技术公司 | 用于治疗神经系统病况的方法和改进的神经保护性组合物 |
IL285232B (en) | 2017-09-14 | 2022-07-01 | Phoenix Biotechnology Inc | Preparations containing oleandrin for the treatment of viral infection |
WO2021154718A1 (en) | 2020-01-27 | 2021-08-05 | Fci Usa Llc | High speed, high density direct mate orthogonal connector |
KR20220151038A (ko) | 2020-03-31 | 2022-11-11 | 피닉스 바이오테크놀러지 인코포레이티드. | 코로나바이러스 감염 예방를 위한 조성물 |
EP4009981B1 (en) | 2020-03-31 | 2023-08-16 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
CN113173965A (zh) * | 2021-04-14 | 2021-07-27 | 籍建亚 | 一种抗肿瘤的白桦酸衍生物及其制备方法 |
CN113173963A (zh) * | 2021-04-14 | 2021-07-27 | 籍建亚 | 一种抗肿瘤的白桦醇衍生物、制备方法及其应用 |
CN113173964A (zh) * | 2021-04-14 | 2021-07-27 | 籍建亚 | 一种抗肿瘤的白桦醇衍生物及其制备方法 |
CN114908645B (zh) * | 2022-04-25 | 2023-08-01 | 杭州傲翔控股有限公司 | 一种机场钢筋混凝土排水沟浇筑施工方法 |
CN115232187B (zh) * | 2022-08-10 | 2024-04-12 | 江西省科学院应用化学研究所 | 一种从龙脑樟中提取7β-羟基白桦脂酸的方法及应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101103986A (zh) * | 2003-09-02 | 2008-01-16 | 叶文才 | 23-羟基白桦酸在制备治疗或预防肝癌药物中的应用 |
CN101730706B (zh) * | 2007-05-11 | 2015-04-15 | 生物科技研究有限公司 | 具有神经保护和增强记忆活性的受体拮抗剂 |
CN101428071B (zh) * | 2007-11-06 | 2012-02-22 | 天津天士力制药股份有限公司 | 一种白头翁的有效组分及其制备方法与用途 |
CN101704872B (zh) * | 2009-11-23 | 2012-06-27 | 张南 | 23-羟基白桦酸衍生物、其制备方法及应用 |
-
2009
- 2009-11-23 CN CN2009101865366A patent/CN101704872B/zh not_active Expired - Fee Related
-
2010
- 2010-05-13 US US13/511,399 patent/US20120302530A1/en not_active Abandoned
- 2010-05-13 WO PCT/CN2010/072740 patent/WO2011060634A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
US20120302530A1 (en) | 2012-11-29 |
WO2011060634A1 (zh) | 2011-05-26 |
CN101704872A (zh) | 2010-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101704872B (zh) | 23-羟基白桦酸衍生物、其制备方法及应用 | |
Zhang et al. | Betulinic acid and the pharmacological effects of tumor suppression | |
Kommera et al. | Carbamate derivatives of betulinic acid and betulin with selective cytotoxic activity | |
ES2281960T3 (es) | Derivados acilados de betulina y dihidrobetulina, su preparacion y su uso. | |
CN101878218A (zh) | 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途 | |
CA3087192A1 (en) | Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents | |
Chrobak et al. | New phosphate derivatives of betulin as anticancer agents: Synthesis, crystal structure, and molecular docking study | |
CN106478569A (zh) | 异土木香内酯衍生物及其盐 | |
Sombut et al. | Synthesis of 14-deoxy-11, 12-didehydroandrographolide analogues as potential cytotoxic agents for cholangiocarcinoma | |
WO2008148269A1 (fr) | Médicament anti-tumoral contenant des dérivés d'acide bétulinique | |
CN104586873B (zh) | 木蝴蝶苷a在制备治疗癌症药物中的应用 | |
CN102030800B (zh) | 杉松三萜类化合物及其提取分离与应用 | |
CN105859823A (zh) | 救必应酸酯类衍生物在制备抗肿瘤药物中的应用 | |
KR20060096147A (ko) | 신규한 트리터펜 유도체, 그 제조방법 및 용도 | |
CN109071437A (zh) | 新型吲哚衍生物和包含其的抗癌组合物 | |
CN101519423B (zh) | 白桦酸类似物、其制备方法和用途 | |
Long et al. | Inhibition of colon cancer cell growth by imidazole through activation of apoptotic pathway | |
CN107987054A (zh) | 一种新型cdk2抑制剂及其抗乳腺癌的应用 | |
CN103483187B (zh) | 4-乙氧基-2-羟基-6-甲基苯甲酸及其药用组合物和应用 | |
CN100374458C (zh) | 17aα-D-高炔雌二醇-3-乙酯及其合成制备方法和以该化合物为活性成分的药物组合物 | |
CN109705189A (zh) | 具有式i所示结构的三萜衍生物及其制备方法和应用 | |
CN107501219A (zh) | 不对称姜黄色素类化合物及其在制备抗胃癌药物中的应用 | |
CN104341407A (zh) | 喹唑啉类化合物及其制备方法和用途 | |
CN103694302B (zh) | 2α,3β-二羟基-30-齐墩果-12,20(29)-二烯-28-酸的制备方法和在制备抗肿瘤药物中的应用 | |
WO2023035130A1 (zh) | 芦荟松在制备治疗溃疡性结肠炎药物中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ZHONG RONG SUZHOU MAIDIXIAN PHARMACEUTICAL TECHNOL Owner name: ZHANG NAN Free format text: FORMER OWNER: SUZHOU MAIDIXIAN PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20110221 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 215125 ROOM 201-G, BUILDING A3, BIOLOGICAL NANOMETER PARK, NO. 218, XINGHU STREET, INDUSTRIAL PARK, SUZHOU CITY, JIANGSU PROVINCE TO: 210008 602, BUILDING 3, NO. 33, JINXIANGHE ROAD, XUANWU DISTRICT, NANJING CITY, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110221 Address after: Jinxiang River Road Xuanwu District of Nanjing Jiangsu province 210008 No. 33 building 3 602 Applicant after: Zhang Nan Co-applicant after: Zhong Rong Co-applicant after: Suzhou Maidixian Medical Technology Co.,Ltd. Address before: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215125 No. 218 BioBAY A3 building room 201-G Applicant before: Suzhou Maidixian Medical Technology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120627 Termination date: 20191123 |